Lexaria Bioscience Corp. (LEXX)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 08-31. Amounts in USD.

Revenue TTM

0 300K 600K 900K Q4 '18: 433.3K Q1 '19: 430.9K Q2 '19: 274.3K Q3 '19: 193.8K Q4 '19: 222.6K Q1 '20: 210.7K Q2 '20: 232.9K Q3 '20: 209.4K Q4 '20: 218K Q1 '21: 503.4K Q2 '21: 657.8K Q3 '21: 825.5K Q4 '21: 722.7K Q1 '22: 441K Q2 '22: 279.6K Q3 '22: 175.3K Q4 '22: 255.4K Q1 '23: 339.3K Q2 '23: 328.6K Q3 '23: 306.6K Q4 '23: 226.2K Q1 '24: 279.8K Q2 '24: 404.7K Q3 '24: 411K Q4 '24: 464.3K Q1 '25: 496.9K Q2 '25: 525.9K Q3 '25: 615.9K Q4 '25: 705.9K Q1 '26: 522K Q2 '26: 368K Q3 '26: 194K Q3 '19 Q3 '20 Q3 '21 Q3 '22 Q3 '23 Q3 '24 Q3 '25 Q3 '26

Gross Profit TTM

-250K 0 250K 500K 750K Q1 '16: -18.8K Q2 '16: -23.7K Q3 '16: -24.3K Q4 '16: -4.9K Q1 '17: 7K Q1 '18: 44.1K Q2 '18: 204.6K Q3 '18: 322.4K Q4 '18: 408.1K Q1 '19: 409.6K Q2 '19: 264K Q3 '19: 183K Q4 '19: 199.7K Q1 '20: 182.1K Q2 '20: 148.9K Q3 '20: 108.2K Q4 '20: 48.9K Q1 '21: 277.6K Q2 '21: 459.6K Q3 '21: 587.6K Q4 '21: 547.4K Q1 '22: 324.5K Q2 '22: 187.4K Q3 '22: 124.4K Q4 '22: 183.6K Q1 '23: 257.2K Q2 '23: 250K Q3 '23: 233.9K Q4 '23: 194.7K Q1 '24: 259.2K Q2 '24: 387.2K Q3 '24: 406.2K Q4 '24: 459.5K Q1 '25: 494.2K Q2 '25: 523.2K Q3 '25: 613.2K Q4 '25: 703.2K Q1 '26: 522K Q2 '26: 368K Q3 '26: 194K Q1 '17 Q1 '19 Q2 '20 Q3 '21 Q4 '22 Q1 '24 Q2 '25 Q3 '26

Operating Income TTM

-15M -10M -5M 0 5M 10M 15M Q1 '16: -2M Q2 '16: -1.8M Q3 '16: -1.6M Q4 '16: -1.3M Q1 '17: -1.3M Q2 '17: -1.5M Q2 '23: -6.2M Q3 '23: -6.2M Q4 '23: -6.5M Q1 '24: -6M Q2 '24: -5.3M Q3 '24: -4.7M Q4 '24: -5.8M Q1 '25: -7.3M Q2 '25: -9.4M Q3 '25: -11.4M Q4 '25: -11.9M Q1 '26: -10.8M Q2 '26: -9.5M Q3 '26: -7.7M Q2 '16 Q1 '17 Q3 '23 Q2 '24 Q1 '25 Q4 '25 Q3 '26

Net Income TTM

-15M -10M -5M 0 5M 10M 15M Q1 '16: -1.8M Q2 '16: -1.7M Q3 '16: -1.4M Q4 '16: -1.2M Q1 '17: -1.2M Q1 '18: -2.1M Q2 '18: -3M Q3 '18: -6.1M Q4 '18: -6.6M Q1 '19: -6.7M Q2 '19: -6.5M Q3 '19: -4.3M Q4 '19: -4.2M Q1 '20: -4.4M Q2 '20: -4.2M Q3 '20: -4.4M Q4 '20: -4.2M Q1 '21: -4M Q2 '21: -2.6M Q3 '21: -3.8M Q4 '21: -4.1M Q1 '22: -5.3M Q2 '22: -7.2M Q3 '22: -7M Q4 '22: -7.3M Q1 '23: -7M Q2 '23: -6.9M Q3 '23: -6.9M Q4 '23: -6.7M Q1 '24: -6.1M Q2 '24: -5.4M Q3 '24: -4.8M Q4 '24: -5.8M Q1 '25: -7.3M Q2 '25: -9.4M Q3 '25: -11.4M Q4 '25: -11.9M Q1 '26: -10.8M Q2 '26: -9.5M Q3 '26: -7.7M Q1 '17 Q1 '19 Q2 '20 Q3 '21 Q4 '22 Q1 '24 Q2 '25 Q3 '26

Cost of Revenue TTM

0 350K 700K 1.1M Q1 '12: 668.2K Q2 '12: 602.4K Q3 '12: 533.8K Q4 '12: 609.8K Q1 '13: 783.3K Q2 '13: 861.2K Q3 '13: 883.2K Q4 '13: 829.2K Q4 '18: 25.2K Q1 '19: 21.2K Q2 '19: 10.2K Q3 '19: 10.9K Q4 '19: 22.9K Q1 '20: 28.6K Q2 '20: 84K Q3 '20: 101.2K Q4 '20: 99.4K Q1 '21: 156K Q2 '21: 128.5K Q3 '21: 168.1K Q4 '21: 175.3K Q1 '22: 116.4K Q2 '22: 92.3K Q3 '22: 50.9K Q4 '22: 71.8K Q1 '23: 82.1K Q2 '23: 78.6K Q3 '23: 72.7K Q4 '23: 31.5K Q1 '24: 20.5K Q2 '24: 17.6K Q3 '24: 4.8K Q4 '24: 4.8K Q1 '25: 2.7K Q2 '25: 2.7K Q3 '25: 2.7K Q4 '25: 2.7K Q1 '26: 0 Q2 '26: 0 Q3 '26: 0 Q1 '13 Q1 '19 Q2 '20 Q3 '21 Q4 '22 Q1 '24 Q2 '25 Q3 '26

Operating Cash Flow TTM

-12M -8M -4M 0 4M 8M 12M Q2 '13: 243.9K Q3 '13: 437.8K Q4 '13: 450.3K Q3 '17: -1.5M Q4 '17: -1.5M Q1 '18: -2M Q2 '18: -2.1M Q3 '18: -2M Q4 '18: -2.5M Q1 '19: -2.6M Q2 '19: -2.6M Q3 '19: -3.1M Q4 '19: -3M Q1 '20: -3M Q2 '20: -3.1M Q3 '20: -2.7M Q4 '20: -2.6M Q1 '21: -2.9M Q2 '21: -3M Q3 '21: -3.5M Q4 '21: -4M Q1 '22: -4.3M Q2 '22: -4.7M Q3 '22: -4.8M Q4 '22: -4.9M Q1 '23: -5M Q2 '23: -4.9M Q3 '23: -5.4M Q4 '23: -5.9M Q1 '24: -5.8M Q2 '24: -5.2M Q3 '24: -4.7M Q4 '24: -5M Q1 '25: -6.5M Q2 '25: -7.4M Q3 '25: -9.7M Q4 '25: -10.5M Q1 '26: -8.7M Q2 '26: -9.4M Q3 '26: -7.4M Q4 '17 Q1 '19 Q2 '20 Q3 '21 Q4 '22 Q1 '24 Q2 '25 Q3 '26

Free Cash Flow TTM

-12M -8M -4M 0 4M 8M 12M Q4 '19: -3.7M Q1 '20: -3.5M Q4 '22: -4.9M Q1 '23: -5M Q2 '23: -4.9M Q3 '23: -5.5M Q4 '23: -5.9M Q1 '24: -5.8M Q2 '24: -5.2M Q3 '24: -4.7M Q4 '24: -5M Q1 '25: -6.6M Q2 '25: -7.4M Q3 '25: -9.8M Q4 '25: -10.5M Q1 '26: -8.7M Q2 '26: -9.4M Q3 '26: -7.5M Q4 '22 Q3 '23 Q2 '24 Q1 '25 Q4 '25 Q3 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 9M 18M 27M Q4 '10: 12.7M Q2 '11: 13M Q3 '11: 13.1M Q4 '11: 14.3M Q2 '12: 16.4M Q3 '12: 16.4M Q4 '12: 16.4M Q1 '24: 9.1M Q2 '24: 10.8M Q3 '24: 13.9M Q1 '25: 16.7M Q2 '25: 17.5M Q3 '25: 18.3M Q1 '26: 21.4M Q2 '26: 24.4M Q3 '26: 24.8M Q2 '11 Q4 '11 Q3 '12 Q1 '24 Q3 '24 Q2 '25 Q1 '26 Q3 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-1.50 -1.00 -0.50 0.00 0.50 1.00 1.50 Q4 '11: -0.04 Q1 '12: -0.04 Q2 '12: -0.04 Q3 '12: -0.04 Q4 '12: -0.02 Q1 '13: -0.02 Q2 '13: -0.02 Q3 '13: -0.01 Q4 '13: -0.01 Q1 '16: -0.04 Q2 '16: -0.04 Q3 '16: -0.04 Q4 '16: -0.04 Q1 '17: -0.04 Q1 '18: -0.04 Q2 '18: -0.05 Q3 '18: -0.09 Q4 '18: -0.09 Q1 '19: -0.09 Q2 '19: -0.08 Q3 '19: -0.04 Q4 '19: -0.04 Q1 '20: -0.36 Q2 '20: -0.73 Q3 '20: -1.22 Q4 '20: -1.45 Q1 '21: -1.36 Q2 '21: -0.89 Q3 '21: -0.89 Q4 '21: -0.89 Q1 '22: -1.00 Q2 '22: -1.34 Q4 '24: -0.47 Q1 '25: -0.50 Q2 '25: -0.59 Q3 '25: -0.67 Q4 '25: -0.65 Q1 '26: -0.56 Q2 '26: -0.47 Q3 '26: -0.34 Q4 '12 Q1 '16 Q1 '18 Q2 '19 Q3 '20 Q4 '21 Q2 '25 Q3 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.